The Opening Volley in the Drug Safety Debate

Mandatory post-marketing studies. It is an idea that has been kicking around on Capitol Hill for at least 30 years. The argument: FDA needs the muscle to force manufacturers to gather additional safety and efficacy information about their products after approval. Voluntary "Phase IV" commitments aren’t good enough.

Advocates of that position have new ammunition after the Government Accountability Office released a report April 24 on FDA’s post-marketing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet